The long view on COVID-19 theranostics and oral antivirals: living with endemic disease and lessons from molnupiravir

Basit Öğe Kaydı
dc.authoridAnmar Al-Taie / 0000-0002-2183-6830en_US
dc.authoridAyşe Şeyma Büyük / 0000-0001-8934-0359en_US
dc.authoridSemra Şardaş / 0000-0001-5456-8636en_US
dc.authoridFatma Rana Denkdemir / 0000-0003-2807-9809
dc.authorscopusidAnmar Al-Taie / 57221579036
dc.authorscopusidAyşe Şeyma Büyük / 57215857903
dc.authorscopusidSemra Şardaş / 7003286974
dc.authorwosidAnmar Al-Taie / I-8549-2019en_US
dc.authorwosidAyşe Şeyma Büyük / AAM-1484-2020en_US
dc.authorwosidSemra Şardaş / J-2175-2018en_US
dc.authorwosidFatma Rana Denkdemir / GMJ-4601-2022
dc.contributor.authorAl-Taie, Anmar
dc.contributor.authorDenkdemir, Fatma Rana
dc.contributor.authorBüyük, Ayşe Şeyma
dc.contributor.authorŞardaş, Semra
dc.date.accessioned2022-05-20T11:42:12Z
dc.date.available2022-05-20T11:42:12Z
dc.date.issued2022en_US
dc.departmentİstinye Üniversitesi, Eczacılık Fakültesi, Eczacılık Meslek Bilimleri Bölümüen_US
dc.description.abstractThe long view on living with COVID-19 as an endemic disease calls for expanding the planetary health inter-vention toolbox. We will need a battery of vaccines, small molecule oral antiviral drugs, and biomarkers toforecast antiviral drug efficacy and safety. In this context, theranostics refers to fusion of therapeutics and diag-nostics. We examine here emerging pathways to theranostics innovation for COVID-19 oral antiviral drugs,with molnupiravir as a case study. With new virus variants (1) variations in the molnupiravir efficacy target,viral RNA-dependent RNA polymerase, (2) variability in pharmacokinetics and exposure to molnupiravir activemoiety in fluids on virus entry points to the host (e.g., saliva, tears, and nasal secretions), (3) variability intransformation from prodrug molnupiravir to its active form, and (4) variability in putative adverse effects onhuman/host cells, all warrant attention for prospects and challenges vis a`vis theranostics innovation forCOVID-19 oral antivirals. The emerging lessons from molnupiravar are of interest to future design of COVID-19theranostic research with other oral antiviral medications. Regulatory agencies, the pharmaceutical industry,research funders, governments, and ministries of health around the world have important stewardship roles toadvance the subpopulation level analyses of clinical trial data on oral antiviral drugs for COVID-19. This wouldremedy the current lag in clinically relevant multiomics theranostics for oral antivirals in the battle againstCOVID-19.en_US
dc.identifier.citationAl-Taie A, Denkdemir FR, Sharief Z, Buyuk AS, Şardaş S. The Long View on COVID-19 Theranostics and Oral Antivirals: Living with Endemic Disease and Lessons from Molnupiravir. OMICS. 2022 May 17. doi: 10.1089/omi.2022.0045. Epub ahead of print. PMID: 35580151.en_US
dc.identifier.doi10.1089/omi.2022.0045en_US
dc.identifier.issn1536-2310en_US
dc.identifier.issue6en_US
dc.identifier.pmid35580151en_US
dc.identifier.scopus2-s2.0-85131902732en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttp://doi.org/10.1089/omi.2022.0045
dc.identifier.urihttps://hdl.handle.net/20.500.12713/2691
dc.identifier.volume26en_US
dc.identifier.wosWOS:000797606000001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorAl-Taie, Anmar
dc.institutionauthorDenkdemir, Fatma Rana
dc.institutionauthorBüyük, Ayşe Şeyma
dc.institutionauthorŞardaş, Semra
dc.language.isoenen_US
dc.publisherAtyponen_US
dc.relation.ispartofOMICS-A JOURNAL OF INTEGRATIVE BIOLOGYen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectCOVID-19en_US
dc.subjectTheranosticsen_US
dc.subjectMolnupiraviren_US
dc.subjectOral Antiviralsen_US
dc.subjectClinical Trialsen_US
dc.subjectBiomarkersen_US
dc.titleThe long view on COVID-19 theranostics and oral antivirals: living with endemic disease and lessons from molnupiraviren_US
dc.typeReview Articleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
omi.2022.0045.pdf
Boyut:
170.48 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Eczacılık Meslek Bilimleri Bölümü Makale Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu